BIORESTORATIVE THERAPIES INC (BRTX)

Company Profile

Biorestorative Therapies Inc. engages in developing therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 10 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells (MSCs), collected from the patient's bone marrow. BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat)-derived stem cells (BADSC) to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Company Info

BIORESTORATIVE THERAPIES INC

40 Marcus Drive

Melville NEW YORK

P: 16317608100

CEO: Lance Alstodt

Employees: 10

Website: https://www.biorestorative.com/